RDGL — VIVOS INC

OTC · Health Care · Health Care Equipment & Supplies · CIK 1449349 ·
Last close
$0.06
Market Cap
$32.10M
52W High
$0.09
52W Low
$0.06
ADV30
1,065,684
Next earnings
Vivos Inc., a radiation oncology medical device company, engages in the development of yttrium-90-based precision radionuclide therapy devices for the treatment of non-resectable tumors in the United States. The company develops RadioGel, which is an injectable particle-gel for Precision Radionuclide Therapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. It is also developing PLGA-g-PEG polymers; PrecisionGel, a hydrogel polymer platform for delivering active pharmaceutical ingredients and therapeutic agents; Duncan Chiller, a general laboratory equipment for non-water localized chilling; and other products under the Alpha-Gel, Beta-Gel, Gamma-Gel, and Peltier Chiller brands. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Kennewick, Washington.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 36,068 -8,018 -545,492 -1,184,845 2,950,505 2,525,782 253,195
Dec 2025 24,752 -3,105 -1,095,719 -1,078,514 1,867,583 1,558,525 206,743
Sep 2025 1,879 -12,815 -531,023 -507,294 2,295,185 2,202,109 112,693
Jun 2025 15,000 -34,753 -674,772 -645,513 2,775,556 2,660,590 96,458

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-2,032,406
Investing CF
$-151,205
Financing CF
$1,547,478
CapEx
$-151,205
Dividends Paid
Buybacks
EPS Diluted TTM
$0.00
As of
2026-06-07

Balance + Analyst (yfinance extras)

Retained Earnings
$-89,612,091
Inventory
$56,863
Receivables
$7,668
ST Investments
EBIT TTM
$-2,847,006
Pretax Income TTM
$-3,416,166
Interest Exp TTM
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$77,699
EBITDA
Free Cash Flow
$-960,187
Enterprise Value
$39,036,660
Total Cash
$2,525,782
Total Debt
$109,593
Shares Out
493,890,608
Trailing EPS
$-0.01
Book Value
$-0.02
ROE
-116.1%
ROA
-56.9%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 68,379 -3,165,047 -3,066,017 1,867,583 206,743 -2,057,743
Dec 2024 27,995 -2,604,384 -2,910,448 2,233,456 86,209 -1,684,039
Dec 2023 19,500 -2,793,146 -2,894,753 1,610,124 245,004 -1,293,023
Dec 2022 36,499 -2,517,749 -2,470,161 1,742,736 81,692 -1,120,058

Peers — same industry

TickerNameMarket CapLastDaily %
MLSS MILESTONE SCIENTIFIC INC. $30.83M $0.35
VASO VASO Corp $33.44M $0.19
NSPR InspireMD, Inc. $34.19M $0.73
PSTV PLUS THERAPEUTICS, INC. $34.49M $5.01
PETV PetVivo Holdings, Inc. $29.32M $0.80

News headlines (Yahoo Finance, 1h cache)

Vivos Receives Washington Radioactive Materials License for IsoPet Manufacturing, Enabling Domestic Production Expansion (RDGL)
2026-06-11 14:51 · Yahoo
Vivos Therapeutics Plans to File for Proposed Rights Offering
2026-06-11 13:11 · Yahoo
Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering
2026-06-11 12:30 · Yahoo
Vivos Inc. Announces Receipt of Washington State Radioactive Materials License for IsoPet® Manufacturing
2026-06-11 12:30 · Yahoo
Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients
2026-06-10 13:03 · Yahoo
Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026
2026-06-08 17:39 · Yahoo
Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing
2026-06-05 12:45 · Yahoo
Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™
2026-06-05 12:30 · Yahoo
Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update
2026-05-20 20:10 · Yahoo
Vivos Therapeutics Reports Full Year 2025 Financial Results
2026-04-15 20:20 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.